

Epilepsies in children & adults: diagnosis & management Advisory Committee Interests Register

Publication Date: 09/03/2022

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL= guideline lead, NGA CA = clinical advisor, NICE
				Interest arose	Interest declared	Interest ceased	
Professor Elizabeth Kay	Chair	Direct - Non-financial professional/personal interest	British Dental Journal Editorial Board	2004	May 2018	<i>Ongoing</i>	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic
Professor Elizabeth Kay	Chair	Direct - Non-financial professional/personal interest	Chair of Management Board of Shirley Glasstone Hughes Foundation	2008	May 2018	<i>Ongoing</i>	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not

							specific to the topic
Professor Elizabeth Kay	Chair	Direct - Non-financial professional/personal interest	Trustee and Vice Chair (since 2014) on the British Medical and Dental Students' Trust	2010	May 2018	<i>Ongoing</i>	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic
Professor Elizabeth Kay	Chair	Direct - Non-financial professional/personal interest	Member of the Dental Tribune Editorial Board	2012	May 2018	<i>Ongoing</i>	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic
Professor Elizabeth Kay	Chair	Direct - Non-financial professional/personal interest	President and Chair of Trustees Board British Dental Health Foundation	2017	May 2018	<i>Ongoing</i>	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not

							specific to the topic
Professor Elizabeth Kay	Chair	Direct - Non-financial professional/personal interest	Member of Editorial Board of International Journal of Dentistry	2012	May 2018	<i>Ongoing</i>	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic
Professor Elizabeth Kay	Chair	Direct - Non-financial professional/personal interest	Non-Executive Director (Associate) Plymouth Hospitals NHS Trusts	2016	May 2018	<i>Ongoing</i>	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic
Professor Elizabeth Kay	Chair	Direct - Non-financial professional/personal interest	Athena Swan Panellist NICE Expert for Guidelines	2012	May 2018	<i>Ongoing</i>	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not

							specific to the topic
Professor Elizabeth Kay	Chair	Direct - Non-financial professional/personal interest	Medical Schools Council Equality Advisory Group	2014	May 2018	<i>Ongoing</i>	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic
Professor Elizabeth Kay	Chair	Direct - Non-financial professional/personal interest	British Dental Association Dental Public Health Committee	2014	May 2018	<i>Ongoing</i>	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic
Professor Elizabeth Kay	Chair	Direct - Non-financial professional/personal interest	British Dental Association Health & Science Committee	2014	May 2018	<i>Ongoing</i>	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not

							specific to the topic
Professor Elizabeth Kay	Chair	Direct - Non-financial professional/personal interest	Chair Joint Trust/University Research Committee	2017	May 2018	Ongoing	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic
Professor Elizabeth Kay	Chair	Direct - Non-financial professional/personal interest	Director of Academic Health Science Network	2017	May 2018	Ongoing	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	Deputy lead, UCL-ICH BRC Clinical Research Facility Theme	2016	August 2018	2021	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not

							specific to the topic
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	Chair, BPNA Research Committee	2015	August 2018	Ongoing	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw.
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	Clinical Advisor, National Children's Epilepsy Surgery Service	2012	August 2018	Ongoing	Declare and partial withdrawal Agreed by GL and NICE CA at recruitment Rationale: will not be actively involved in drafting recommendations in this area
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial	Member, Paediatric Medicines Expert Advisory Group, MHRA	2015	August 2018	Ongoing	Declare and participate

		professional/personal interest					<p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw as this group is not specific to epilepsy and has no decision making capacity.</p>
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	Treasurer (elected) International League Against Epilepsy	2017	August 2018	2021	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw.</p>

Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	Co-ordinator, ERN EpiCARE for rare & complex epilepsies	2017	August 2018	2022	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw.
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	Appointed to sub panel 1, clinical Medicine REF2021 review on cannabidiol	2018	August 2018	2021	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic as cannabidiol will not be addressed in this guideline
Helen Cross	Committee Member, Topic Advisor	Direct – financial	GW Pharma, investigator in cannabidiol studies; remuneration to department	2015	August 2018	2019	Declare and participate

							<p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Interest is not specific to the topic as cannabidiol will not be addressed in this guideline</p>
Helen Cross	Committee Member, Topic Advisor	Direct – financial	Zogenix, investigator in fenfluramine studies, remuneration to department	2016	August 2018	2018	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Activity ended over 1 year before pharmacology was addressed by the committee and the member did not personally benefit financially.</p>
Helen Cross	Committee Member, Topic Advisor	Direct - financial	GW Pharma advisory board on CBD in Dravet and Lennox	2018	August 2018	2018	<p>Declare and participate</p>

			Gastaut syndrome, remuneration to department				<p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Interest is not specific to the topic as cannabidiol will not be addressed in this guideline and the member did not personally benefit financially.</p>
Helen Cross	Committee Member, Topic Advisor	Direct - financial	Zogenix ,speaker at symposia, remuneration to department	2016	August 2018	2018	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Activity ended over 1 year before pharmacology was addressed by the committee and the member did not personally</p>

							benefit financially.
Helen Cross	Committee Member, Topic Advisor	Direct - financial	Vitaflo (products for a ketogenic diet), investigator in study, remuneration to department	2014	August 2018	Ongoing	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Declare and partial withdrawal</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: will not be actively involved in drafting recommendations in this area.</p>
Helen Cross	Committee Member, Topic Advisor	Direct - financial	Nutricia, speaker at symposium, remuneration to department	2016	August 2018	2018	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Activity ended over 1 year before</p>

							pharmacology was addressed by the committee and the member did not personally benefit financially.
Helen Cross	Committee Member, Topic Advisor	Direct - financial	Educational grant from Sanofi for meeting development	2015	August 2018	2018	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Activity ended over 1 year before pharmacology was addressed by the committee and the member did not personally benefit financially.
Helen Cross	Committee Member, Topic Advisor	Direct - financial	Investigator and grant holder, Development and Epilepsy - Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult to treat	2013	August 2018	2018	Declare and participate Agreed by GL and NICE CA at recruitment

			Epilepsy (DESIRE) FP7-HEALTH-2013-INNOVATION-1 E11,995,646				Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw and the member did not personally benefit financially.
Helen Cross	Committee Member, Topic Advisor	Direct - financial	Leader of workpackage, Chief Investigator clinical trial of ketogenic diet in cortical dysplasia prior to surgery, E900,000	2013	August 2018	2018	Declare and partial withdrawal Agreed by GL and NICE CA at recruitment Rationale: will not be actively involved in drafting recommendations in this area and the member did not personally benefit financially.

Helen Cross	Committee Member, Topic Advisor	Direct - financial	A randomised controlled trial of the ketogenic diet in the treatment of epilepsy in children under the age of two years (Chief Investigator) JH Cross. F O'Callaghan, A Parker, S Philip, R Williams, L Neal, C Ferrie, T Martland, N Freemantle, I Nazereth, L Marston, C Eltze, S Heales, R Kneen NIHR EME £1,242,999.40	2015	August 2018	Ongoing (until 2021)	Declare and partial withdrawal Agreed by GL and NICE CA at recruitment Rationale: will not be actively involved in drafting recommendations in this area and the member did not personally benefit financially.
Helen Cross	Committee Member, Topic Advisor	Direct - financial	A European Reference Network for Rare and Complex Epilepsies (EpiCARE) Chafea E 195,975.18	2017	August 2018	2019	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw and the member did

							not personally benefit financially.
Helen Cross	Committee Member, Topic Advisor	Direct - financial	Effect of paroxysmal events in early onset neurological disease on cerebral tissue oxygenation & metabolism: a NIRS pilot study JH Cross (Chief investigator) A Vezyroglou, I Tachtsidis, R Thornton, D Carmichael S Sisodiya Great Ormond Street Hospital Charity £68,608.69	2017	August 2018	2018	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic and the member did not personally benefit financially.
Helen Cross	Committee Member, Topic Advisor	Direct - financial	Transforming the mental health treatment of young people with epilepsy R Shafran, JH Cross (Co Chief investigator) T Ford, T Stephenson, R Moss-Morris, C Dore, S Varadkar, J Smith, S Tebbs, S Byford, P Fonagy, I Heyman NIHR PGfAR £2,208,680.00	2018	August 2018	Ongoing (until 2023)	Declare and partial withdrawal Agreed by GL and NICE CA at recruitment Rationale: will not be actively involved in drafting recommendations in this area and the member did not

							personally benefit financially.
Helen Cross	Committee Member, Topic Advisor	Direct - financial	Enabling Clinical Decisions from Low-power MRI in developing nations through image quality transfer Alexander D, Lagunju I, Fernandez Reyes D, Cross JH, Carmichael D, Ghosh A. EPSRC Global Challenges Research Fund £1,018,948.68	2018	August 2018	Ongoing (until 2021)	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw, as not specific to UK
Helen Cross	Committee Member, Topic Advisor	Direct - financial	NIHR Children and Young Peoples MedTech Cooperative Dimitri P, Cross JH (Co-investigator) NIHR £1,107,971.85	2018	August 2018	Ongoing	Declare and partial withdrawal Agreed by GL and NICE CA at recruitment Rationale: will not be actively involved in drafting recommendations in this area

							and the member did not personally benefit financially.
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	<p>Contributed to the following books:</p> <ol style="list-style-type: none"> 1. Aldenkamp A, Arzimanoglou A, Cross H, Lassonde M, Moshe S, Schmitz B ed. <i>Cognitive dysfunction in children with temporal lobe epilepsy</i> John Libbey; Paris 2005. P1-289 2. Alarcon G, Nashef L, Cross H, Nightingale J, Richardson S. <i>Epilepsy</i>. Oxford Specialist Handbooks in Neurology; Oxford University Press 2009. 3. Duchowny M, Cross J Helen, Arzimanoglou A ed. <i>Pediatric Epilepsy</i> McGraw Hill. China 2013. (Contribution of five chapters; three sole authorship) 4. Nation J, Cross JH, Scheffer IE, <i>Ketocooking; a practical guide to the ketogenic diet</i> The Homewood Press, 2012. 5. Malmgren K, Cross JH, Baxendale S ed. <i>Long term</i> 	2004	August 2018	2016	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw, as book chapters will not form part of the evidence base.</p>

			<p><i>outcome of epilepsy surgery.</i> Springer New York 2015.</p> <p>6. Moshe S, Cross JH, de Bellescize J, Nordli D, Vigevano F, de Vries L ed <i>Seizures and syndromes of onset in the first two years of life</i> ed John Libbey Eurotext Paris 2015</p> <p>7. Arzimanoglou A, Cross JH, Gaillard WG, Holtshausen H, Jayakar P, Kahane P, Mathern G.ed <i>Pediatric Epilepsy Surgery</i> John Libbey Eurotext Paris 2016. <i>(Contribution of three chapters: two sole authorship)</i></p>				
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	<p>Contributed to publications:</p> <p>1. Harvey AS, Cross JH, Shinnar S, Mathern G W and the Paediatric Epilepsy Surgery Survey Taskforce. Defining the spectrum of international practice in paediatric epilepsy surgery patients. <i>Epilepsia</i> 2008;49:</p> <p>2. Boshuisen K, Arzimanoglou A, Cross JH, Uiterwaal C.S.P.M, Polster T, van Nieuwenhuizen O, Braun</p>	2008	August 2018	2014	<p>Declare and partial withdrawal</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: will not be actively involved in drafting recommendations in this area and the member</p>

			<p>K.P.J. for the 'TimeToStop' study group. Timing of AED withdrawal does not influence long-term seizure outcome after paediatric epilepsy surgery. The 'TimeToStop' study. Lancet Neurol. 2012 Sep;11(9):784-91</p> <p>3. Jayakar P, Gaillard WG, Tripathi M, Libenson M, Mathern GW, Cross JH on behalf of the Task Force for Paediatric Epilepsy Surgery, Commission for Paediatrics, and the Diagnostic Commission of the International League Against Epilepsy. Diagnostic Test Utilization in Evaluation for Resective Epilepsy Surgery in Children; Recommendations on behalf of the Task Force for Paediatric Epilepsy Surgery (of the Commission for Paediatrics) * and the Diagnostic Commission of the ILAE. Epilepsia, 2014; 55(4):507-518,</p>				did not personally benefit financially.
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	<p>Contributed to publications:</p> <p>1. Neal EG, Chaffe HM, Edwards N, Lawson M, Schwartz R, Fitzsimmons G,</p>	2008	August 2018	2018	Declare and partial withdrawal

			<p>Whitney A, Cross JH The ketogenic diet in the treatment of epilepsy in children: a randomised, controlled trial. Lancet Neurology 2008;7:500-506</p> <p>2. Neal EG, Chaffe HM, Edwards N, Lawson M, Schwartz R, Fitzsimmons G, Whitney A, Cross JH A randomised trial of classical and medium chain triglyceride diets in the treatment of childhood epilepsy Epilepsia 2009;50:1109-1117</p> <p>3. Augustin K, Khabbush A, Williams S, Eaton SJ, Orford M, Cross JH, Heales SJ, Walker M, Williams R Medium chain triglyceride ketogenic diet in neurological and metabolic disorders Lancet Neurology 2018;17:84-93</p>				<p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: will not be actively involved in drafting recommendations in this area and the member did not personally benefit financially.</p>
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	Gaillard WD, Chiron C, Cross J Helen, Harvey A Simon , Kuzniecky R, Hertz-Pannier L, Gilbert Vezina L. Guidelines for imaging infants and children with recent-onset epilepsy Epilepsia. 2009;50(9):2147-53	2009	August 2018	2009	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: despite this</p>

							being a specific interest, the balance of risks is such that there is no need to withdraw.
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	<p>Contributed to publications:</p> <ol style="list-style-type: none"> 1. Berg AT, Berkovic SF, Buchhalter J, Engel J Jr, Glauser TA, Nordli D, Plouin P, Ryvlin P, Scheffer IE, von Emde Boas W, French J, Cross JH, Mathern GW, Ottman R, Wolf P, Moshe SL, Brodie M.. Report of the Commission on Classification and Terminology: Update and recommendations. <i>Epilepsia</i> 2010;51:676-685 2. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger C, Engel JJ, Jr, French JA, Glynn M, Hesdorffer DC, Lee B-I, Mathern G, Moshé SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. An Operational Clinical Definition of Epilepsy <i>Epilepsia</i> 2014;55:475-482 3. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, 	2010	August 2018	2017	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw.</p>

			<p>Jansen FE, Lagae L, Moshé SL, Peltola J, Roulet Perez E, Scheffer IE, Zuberi SM. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. <i>Epilepsia</i>. 2017 Apr;58(4):522-530</p> <p>4. Eltze CM, Chong WK, Cox T, Whitney A, Cortina-Borja M, Chin RFM, Scott RC, Cross JH A population based study of newly diagnosed epilepsy in children in the first two years of life <i>Epilepsia</i> 2013;54:437-445</p>				
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	<p>Contributed to publications:</p> <p>1. Varadkar SM, Bien CG, Kruse CA, Jensen FE, Bauer J, Pardo CA, Vincent A, Mathern GW, Cross JH. Rasmussens Encephalitis: Current Concepts & Therapeutic Advances <i>Lancet Neurol</i> 2014 Feb;13(2):195-205</p>	2014	August 2018	2015	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Interest is not specific to the topic as Rasmussens Encephalitis</p>

			2. Pressler R, Boylan, GB, Blennow, M; Chiron, C; Cross JH, de Vries, LS; Hallberg, B; Hellstrom-Westas, L; Jullien, V; Livingstone, V; Mangum, B; Marlow, N; Murphy, B; Murray, D; Pons, G; Rennie, J; Swarte, R; Toet, M; Vanhatalo, S; Zohar S: Evaluation of bumetanide as second line treatment for neonatal seizures in a phase I/II dose finding and feasibility trial (NEMO) Lancet Neurol. 2015 May;14(5):469-77				and the treatment of neonates is outside the scope of this guideline.
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	MacTague A, Howells KB, Cross JH, Kurian MA, Scheffer IE. The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol; 2016;15:304-316	2015	August 2018	2016	Declare and partial withdrawal Agreed by GL and NICE CA at recruitment Rationale: not specific as the guideline will not focus on the pathophysiology of epilepsies

Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	Wadsworth I, Jaki T, Sills GJ, Appleton R, Cross JH, Marson AG, Martland T, McLellan A, Smith PE, Pellock JM, Hampson LV. Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using Extrapolation. CNS Drugs. 2016 Nov;30(11):1011-1017.	2015	August 2018	2016	Declare and partial withdrawal Agreed by GL and NICE CA at recruitment Rationale: not specific as this is a methodology paper
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	Harden C, Tomson T, Gloss D, Buchhalter JR, Cross JH, Donner EJ, French J, Gil-Nagel A, Hesdorffer D, Smithson WH, Spitz MC, Walczak TS, Sander JW, and Ryvlin P. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society Neurology	2016	August 2018	2017	Declare and partial withdrawal Agreed by GL and NICE CA at recruitment Rationale: will not be actively involved in drafting recommendations in this area

			2017 Apr 25;88(17):1674-1680				
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	<p>Contributed to publications:</p> <ol style="list-style-type: none"> 1. Devinsky O*, Cross JH* , Laux L, Marsh, E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S, for The Cannabidiol in Dravet Syndrome Study Group. Trial of Cannabidiol for Drug Resistant Seizures in Dravet Syndrome NEJM -2017;376:2011-2020 2. Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood S, Roberts C, Checketts D, VanLandingham K, Zuberi SM. Effect of Cannabidiol on Drop Seizures in Lennox-Gastaut Syndrome NEJM N Engl J Med 2018;378:1888-97. 	2016	August 2018	2018	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Interest is not specific to the topic as cannabidiol will not be addressed in this guideline</p>
Helen Cross	Committee Member, Topic Advisor	Direct - Non-financial professional/personal interest	<p>Wilmshurst JM, Guekht A, Secco M, Cross JH, Perucca E on behalf of the Advocacy Task Force, Commission of Pediatrics, International League Against Epilepsy Advocacy for Children</p>	2016	August 2018	Ongoing (in press)	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p>

			with Epilepsy: Leveraging the WHA Resolution. Epilepsia Open in press				Rationale: not directly related to the topic of the guideline
Rachel Batchelor	Committee Member, Lay member	Direct - Non-financial professional/personal interest	Paper published in 'Epilepsy and Behaviour' - Young adults with epilepsy: Relationships between psychosocial variables and anxiety, depression, and suicidality	March 2021	March 2021	March 2021	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw.
Christine Cole	Committee Member, Nurse specialist (adults)	Direct - Non-financial professional/personal interest	Contributed to publications: 1. Pointu A & Cole C (2005) An education programme for social care staff: improving the health of people who have a learning disability and epilepsy. British Journal for Learning Disabilities (BILD). 33, 39-43. 2. Cole C & Pointu A (2007) Epilepsy awareness and the administration of rectal	2004	April 2019	2015	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: despite this being a specific interest, the balance of risks is such that

			<p>diazepam. Learning Disability Practice. Vol. 10. No.1.10-15</p> <p>3. Burt J & Cole C (2008) Swimming guidelines for adults with epilepsy. Learning Disability Practice. Vol.11. No.10. 12-16..</p> <p>4. These swimming guidelines are accessible in print as a leaflet from Barnet Mencap - for people who have epilepsy</p> <p>5. Cole C, Pointu A, Mahadeshwar S, Dudley A (2009) Community Survey of carer's: Individual epilepsy guidelines (IEG) for rescue medication. Seizure Vol.18. No3. 220-224</p> <p>6. Edited by Bob Gates & Owen Barr (2009) Oxford Handbook of Learning and Intellectual Disability Nursing. 1st Edition Oxford University Press. UK.</p> <p>Contributed the following sections:</p> <p>7. Supporting people in mainstream health services.Epilepsy Specialist</p>				there is no need to withdraw.
--	--	--	--	--	--	--	-------------------------------

			<p>nurse. Chapter 10 supporting people: 394-395.</p> <p>8. Physical health and well being, Independent Nurse Prescribers in Intellectual Disability. Chapter 6, 210-211.</p> <p>9. Cole C, Pointu A, Wellsted DM, Angus-Leppan H (2010) A pilot study of the Epilepsy Risk Awareness Checklist (ERAC): in people with epilepsy and learning disabilities. Seizure, Vol. 19, 592-596.</p> <p>10. Cole C & Burt J (2011) Using Aromatherapy & Massage with clients who have complex intellectual disabilities – a day centre project. Learning Disability Practice- December. Vol.14. No.10. 25-29</p> <p>11. Learning Disability Nursing At a Glance (2015). Edited by Bob Gates Debra Fearn Jo Welch. Wiley Blackwell.</p>				
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial	Remunerated Advisory board for Nutricia 1 day	June 2018	February 2019	June 2018	Declare and participate

							Agreed by GL and NICE CA at recruitment Rationale: Activity ended over 1 year before pharmacology was addressed by the committee
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial	Remunerated speaker at conference sponsored by Nutricia 1 day	October 2017	February 2019	October 2017	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Activity ended over 1 year before pharmacology was addressed by the committee
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial	Remunerated Advisory Board work for Zogenix 1 day	October 2017	February 2019	October 2017	Declare and participate Agreed by GL and NICE CA at recruitment

							Rationale: Activity ended over 1 year before pharmacology was addressed by the committee
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial	Reumunerated speaker at a conference sponsored by Vitaflo 1 day	March 2018	February 2019	March 2018	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Activity ended over 1 year before pharmacology was addressed by the committee
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial	Principal Investigator for industry sponsored portfolio adopted study on new ketogenic diet product	2017	February 2019	2018	Declare and partial withdrawal Agreed by GL and NICE CA at recruitment Rationale: will not be actively involved in

							drafting recommendations in this area
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Non-financial professional/personal interest	Principal Investigator for Ketogenic Diet in infants with epilepsy (KIWE) study (NIHR EME) – multicentre national study of efficacy of the KD in the under 2 years age group (no funding received)	2017	February 2019	Ongoing	Declare and partial withdrawal Agreed by GL and NICE CA at recruitment Rationale: will not be actively involved in drafting recommendations in this area
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial	Wellcome sponsored programme grant IVF and mitochondrial donation – One of two investigators assessing neurodevelopmental outcome of cohort of offspring	2017	February 2019	Ongoing	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial	Collaboration with Professor M Cunningham, Institute of Neuroscience, Newcastle University to bring together 3	2017	February 2019	2017	Declare and participate

			month research project for ACF trainee in laboratory (completed)				Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial	Industry advisory board - the interpretation of results from a study of a new drug treatment for epilepsy and advising on advantages and barriers to implementation	2017	February 2019	2017	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Activity ended over 1 year before pharmacology was addressed by the committee and the member did not personally benefit financially
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial	Industry advisory board – launch of a new ketogenic product, currently participating in the trial, initial feedback and advice on where it fits in terms of treatment for children	2017	February 2019	2017	Declare and participate Agreed by GL and NICE CA at recruitment

							Rationale: will not be actively involved in drafting recommendations in this area
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Non-financial professional/personal interest	Member of the Board of Trustees Young Epilepsy	2012	February 2019	Nov 2020	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Despite this being a specific interest, the balance of risks is such that there is no need to withdraw</p>
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Non-financial professional/personal interest	Member of the Medical Board of Matthew's Friends	2015	August 2018	Ongoing	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Despite this being a specific interest, the balance of risks is such that</p>

							there is no need to withdraw
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Non-financial professional/personal interest	Clinical member of clinical reference group NHSE Paediatric Neurosciences	2016	August 2018	Ongoing	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Despite this being a specific interest, the balance of risks is such that there is no need to withdraw</p>
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Non-financial professional/personal interest	Course Director, national faculty Paediatric Epilepsy Training Courses. No remuneration received.	2004	February 2019	Ongoing	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Despite this being a specific interest, the balance of risks is such that there is no need to withdraw</p>

Anita Devlin	Committee Member, Paediatric neurologist	Direct - Non-financial professional/personal interest	Founding faculty member and author of course materials for KetoCollege UK. No remuneration received.	2016	February 2019	Ongoing	Declare and partial withdrawal Agreed by GL and NICE CA at recruitment Rationale: will not be actively involved in drafting recommendations in this area
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Non-financial professional/personal interest	Ipsen CLIMB course (Continuum of Learning to Improve Management with Botulinum Toxin) – invited to contribute to course materials and feedback and then to become a teaching centre of excellence within Europe	2018	February 2019	Ongoing	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: Interest is not specific to the topic
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Non-financial professional/personal interest	Contributed to publications: 1. Anita Devlin, Ketogenic diet: Seizure-control effectiveness of a high-fat diet, <i>Epilepsy Professional</i> 2017:44;12-17 2. Bruce S, Devlin A, Air L, Cook L, Changes in quality of life as a result of ketogenic diet	2016	February 2019	2017	Declare and partial withdrawal Agreed by GL and NICE CA at recruitment Rationale: will not be actively

			<p>therapy: A new approach to assessment with the potential for positive therapeutic effects. <i>Epilepsy Behav.</i> 2017 Jan;66:100-104. doi:10.1016/j.yebeh.2016.10.001. Epub 2016 Dec 27PMID: 28038385 [PubMed - in process]</p> <p>3. Upasana Gurunathan, Lucy B Bellis, Ann B Bowron, Linda A Air, Anita M Devlin, Acylcarnitine profiles and their association with efficacy in the ketogenic diet. Poster presentation by SSC student, abstract published <i>Developmental Medicine and Child Neurology</i>; Jan 2017</p>				involved in drafting recommendations in this area
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Non-financial professional/personal interest	<p>Contributed to publications:</p> <ol style="list-style-type: none"> Basu A, Brown S, Kirkham N, Ramesh V, Leech S, Devlin A. Coma blisters in 2 children on anticonvulsant medication. <i>J Child Neurol.</i> 2009 Aug;24(8):1021-5 Epub 2009 Apr 8. PubMed PMID: 19359256. Lawlor KM, Devlin AM. Levetiracetam in the treatment of infantile spasms. <i>Eur J Paediatr Neurol.</i> 2005;9(1):19- 	2004	February 2019	2009	<p>Declare and partial withdrawal</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: will not be actively involved in drafting recommendations for this drug</p>

			22.Epub 2004 Dec 25. PubMed PMID: 15701562				
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Non-financial professional/personal interest	<p>Contributed to publications:</p> <ol style="list-style-type: none"> 1. Symonds JD, Joss S, Metcalfe KA, Somarathi S, Cruden J, Devlin AM, Donaldson A, DiDonato N, Fitzpatrick D, Kaiser FJ, Lampe AK, Lees MM, McLellan A, Montgomery T, Mundada V, Nairn L, Sarkar A, Schallner J, Pozojevic J, Parenti I, Tan J, Turnpenny P, Whitehouse WP; DDD Study, Zuberi SM. Heterozygous truncation mutations of the SMC1A gene cause a severe early onset epilepsy with cluster seizures in females: Detailed phenotyping of 10 new cases. <i>Epilepsia</i>. 2017 Apr;58(4):565-575. doi: 10.1111/epi.13669. Epub 2017 Feb 6. PMID: 28166369 [PubMed - in process] 2. Anita Devlin. Paediatric neurological examination. <i>Advances in Psychiatric Treatment</i>. 2003;9:125-134. 3. Devlin AM, Cross JH, Harkness W, Chong WK, Harding B, Vargha-Khadem F, 	2002	February 2019	2017	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Despite this being a specific interest, the balance of risks is such that there is no need to withdraw</p>

			<p>Neville BG. Clinical outcomes of hemispherectomy for epilepsy in childhood and adolescence. Brain. 2003 Mar;126(Pt 3):556-66. PubMed PMID: 12566277.</p> <p>4. 2009 & 2016 Invited chapter on management of acute seizures and status epilepticus for Oxford Specialist handbook of Paediatric Oncology</p>				
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Non-financial professional/personal interest	<p>Contributed to the publication: Augustin K, Williams S, Cunningham M, Devlin A, Friedreich M, Jayasekera A, Hussein M, Holliman D, Mitchell P, Jenkins A, Chen P, Walker M, Williams R</p> <p>Perampanel and decanoic acid show synergistic action against AMPA receptors and seizures Epilepsia 2018;59;1-7</p>	August 2018	July 2019	August 2018	
Anita Devlin	Committee Member, Paediatric neurologist	Direct – Financial professional/personal interest	Invited speaker at Complex Epilepsy conference agreed before appointed to NICE guideline committee	August 2019	December 2019	August 2019	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Despite this being a specific interest, the</p>

							balance of risks is such that there is no need to withdraw
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Non-financial professional/personal interest	Attendee at Livanova VNS Masterclass as part of CPD – travel and accommodation provided	November 2019	December 2019	November 2019	Declare and participate Agreed by GL Rationale: will not be actively involved in drafting recommendations in this area
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial professional/personal interest	Remunerated national Webinar on diagnosis and treatment of Lennox-Gastaut syndrome excluding CBD treatment for GW Pharma	April 2020	August 2020	April 2020	Declare and participate Agreed by GL Rationale: Despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial professional/personal interest	Remunerated International Medical Press live webinar on ketogenic dietary therapy	Jan 2021	Feb 2021	Jan 2021	Declare and participate Agreed by GL

							Rationale: Despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial professional/personal interest	Remunerated Nutricia sponsored podcast on treatment options once drugs have failed	Dec 2020	Feb 2021	Dec 2020	Declare and participate Agreed by GL Rationale: Despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial professional/personal interest	Remunerated national Webinar on diagnosis and treatment of Lennox-Gastaut syndrome excluding CBD treatment for GW Pharma	April 2020	Feb 2021	April 2020	Declare and participate Agreed by GL Rationale: Despite this being a specific interest, the balance of risks is such that there is no need to withdraw

Anita Devlin	Committee Member, Paediatric neurologist	Direct - Financial professional/personal interest	Presenter GW Pharma sponsored symposium at Association of British Neurologists annual conference on diagnosis of Lennox-Gastaut syndrome and transition to adult care – no treatments were referred to	May 2021	May 2021	May 2021	Declare and participate Agreed by GL Rationale: Despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Diane Flower	Committee Member, Clinical Nurse (children)	Direct - Non-financial professional/personal interest	Co-author of Dorris L, Broome H, Wilson M, Grant C, Young D, Baker G, Balloo S, Bruce S, Campbell J, Concannon B, Conway N, Cook L, Davis C, Downey B, Evans J, Flower D, Garlovsky J, Kearney S, Lewis S, Stephens V, Turton S, Wright I (2017) A randomized controlled trial of a manual-based psychosocial group intervention for young people with epilepsy [PIE]. <i>Epilepsy & Behaviour</i> 72 89-98.	2015	February 2019	2017	Declare and partial withdrawal Agreed by GL and NICE CA at recruitment Rationale: will not be actively involved in drafting recommendations in this area
Diane Flower	Committee Member, Clinical Nurse (children)	Direct - Non-financial professional/personal interest	Member of the Joint Epilepsy Council (JEC) Working Party for the development of guidelines on buccal midazolam use in epilepsy, 2005.	2005	February 2019	2005	Declare and participate

							<p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw, as unlikely to form part of the evidence base.</p>
Diane Flower	Committee Member, Clinical Nurse (children)	Direct – Non-financial	Member of the Methodology Group for the current Epilepsy12 audit. Involvement in establishing and developing the methodology and dataset for the audit.	2017	June 2019	Ongoing	<p>Declare and participate</p> <p>Agreed by GL and Chair</p> <p>Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw</p>
Diane Flower	Committee Member, Clinical Nurse (children)	Direct - Non-financial professional/personal interest	<p>Contributed to publications:</p> <ol style="list-style-type: none"> 1. Bairstow K., Chantler K., Chisanga E., Flower D. et al (2005) A guideline on training 	2004	February 2019	2014	Declare and participate

			<p>standards for the administration of buccal midazolam. Joint Epilepsy Council of the UK and Ireland, Leeds.</p> <p>2. Flower D. (2009) Epilepsy part 1: Recognizing seizure types and diagnosis. British Journal of School Nursing 4(3) 113-118.</p> <p>3. Flower D. (2009) Epilepsy part 2: Treatments and emergency medication. British Journal of School Nursing. 4(4) 164-169.</p> <p>4. Flower D. (2009) Epilepsy part 3: Planning for emergencies. British Journal of School Nursing. 4(5) 164-168.</p> <p>5. Flaum N., Barber M., Lewis H., Capeling L., Flower D. (2010) A survey of special educational needs coordinators' (SENCOS') knowledge, attitudes and awareness of epilepsy, and potential impact on children and young people in mainstream primary and secondary schools: an all Gwent perspective. International League Against Epilepsy UK Chapter Annual</p>				<p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw</p>
--	--	--	---	--	--	--	---

			<p>Scientific Meeting Abstracts 36-37.</p> <p>6. Flower D. (2011) Drug focus: Pharmacological options in the treatment of epilepsy. Nurse Prescribing 9(7) 332 - 341.</p> <p>7. Royal College of Nursing (2013) Specialist nursing of children and young people with epilepsy. RCN guidance for service planning and career development. Royal College of Nursing, London.</p> <p>8. Kirkpatrick M, Dunkley C, Ferrie C, Flower D, Waldron B, Whitehouse W, Cross JH, Rodie P, Appleton R. (2014) Guidelines, training, audit, and quality standards in children's epilepsy services: Closing the loop. Seizure 23(10) 864–868.</p>				
Richard Grunewald	Committee Member, Adult Neurologist	Direct - Financial	Received sponsorship to deliver training on botulinum toxin treatment by Ipsen pharma to the value of about £600, and later this year a similar amount for botulinum toxin injection training sponsored by Allergan. Neither company have licensed antiepileptic drugs, and I am aware of no antiepileptic drugs or	2019	April 2019	2019	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Interest is not</p>

			therapies planned by either company in the future I received sponsorship this year from both Merz and Ipsen to attend european conferences on botulinum toxins, including second class air travel, conference registration fees and hotel accommodation, value about £800 each. Neither company has any interest in anti epileptic medication				specific to the topic
Richard Grunewald	Committee Member, Adult Neurologist	Direct - Financial	Neurology medicolegal reporting	2003	April 2019	Ongoing	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: committee member has agreed to refrain from undertaking any medicolegal work relating to epilepsy until the guideline is published
Richard Grunewald	Committee Member, Adult Neurologist	Direct - Non-financial	Dickson JM, Taylor LH, Shewan J, Baldwin T, Grünewald RA, Reuber M. Cross-sectional study of the prehospital management of	2015	April 2019	2016	Declare and participate

		professional/personal interest	adult patients with a suspected seizure (EPIC1) BMJ Open 6(2):e010573-e010573 Feb 2016.				Agreed by GL and NICE CA at recruitment Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Richard Grunewald	Committee Member, Adult Neurologist	Direct - Non-financial professional/personal interest	I have been asked to write a paper for British Journal of Hospital medicine on psychogenic non-epileptic seizures. No payment is involved.				Declare and participate Agreed by GL and NICE CA at recruitment Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Richard Grunewald	Committee Member, Adult Neurologist	Direct - Non-financial professional/personal interest	Co-author of ESPENTE study	August 2019	November 2019	Ongoing	Declare and participate Agreed by GL Rationale: despite this being a specific

							interest, the balance of risks is such that there is no need to withdraw
Sarah Hughes	Committee Member, Paediatrician	Direct - Non-financial professional/personal interest	Regional representative on BACD Executive committee (British Association of Childhood disability)	2012	Feb 2019	Ongoing	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Sarah Hughes	Committee Member, Paediatrician	Direct - Non-financial professional/personal interest	Lecturer at Reading university – language pathology course and Physician’s associate course – 4 lectures per year.	2012	Feb 2019	Ongoing	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: despite this being a specific interest, the balance of risks is such that

							there is no need to withdraw
Sarah Hughes	Committee Member, Paediatrician	Direct - Non-financial professional/personal interest	Part of RCPCH EQIP project looking at quality improvement work in epilepsy. Funded by RCPCH. Included an away weekend funded by RCPCH. No financial exchange.	October 2019	October 2019	May 2020	Declare and participate Agreed by GL in October 2019. Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Sarah Hughes	Committee Member, Paediatrician	Direct - Non-financial professional/personal interest	Principal investigator for the Parrot study – not directly related to epilepsy but some of those recruited had epilepsy. Looking to see if antibiotics reduce hospitalisation in sick children/young people with complex needs.	October 2019	October 2019	Ongoing	Declare and participate Agreed by GL in October 2019. Rationale: Interest is not specific to the topic
Sarah Hughes	Committee Member, Paediatrician	Direct - Non-financial professional/personal interest	Contributed to a collaborative paper accepted by Neurology (Genetics) which is non-epileptic based, and to which I have contributed case details with parental consent.	December 2020	December 2020	December 2020	Declare and participate Agreed by GL. Rationale: Interest is not

							specific to the topic
Harriet Joy	Co-opted Committee Member, Neuroradiologist	Direct - Non-financial professional/personal interest	Independent member of the trial steering committee for a national multicentre trial - the MERIDIAN study (Magnetic resonance imaging to enhance the diagnosis of fetal developmental brain abnormalities)	2011	April 2019	2018	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Interest is not specific to the topic the treatment of neonates is outside the scope of this guideline.</p>
Harriet Joy	Co-opted Committee Member, Neuroradiologist	Direct - Non-financial professional/personal interest	<p>Contributed to publications:</p> <ol style="list-style-type: none"> 1. Fetal and Neonatal Brain Magnetic Resonance Imaging: Clinical Indications, Acquisitions and Reporting, a Framework for Practice. Published by BAPM (British Association of Perinatal Medicine) in February 2016. 2. Imaging of the developing brain: guidelines for paediatric, neonatal and fetal brain imaging – available on the website of the BSNR 	2016	April 2019	2017	<p>Declare and participate</p> <p>Agreed by GL and NICE CA at recruitment</p> <p>Rationale: Interest is not specific to the topic the treatment of neonates is outside the scope of this guideline.</p>

			(British Society of Neuroradiologists)				
Angie Pullen	Committee Member, Lay member	Direct - Financial	Payment received by Epilepsy Action from marketing authorisation holders and/or manufacturers of antiepileptic drugs (branded or generic) plus LivaNova (formerly Cyberonics, device manufacturer of VNS, a treatment for epilepsy) for advice and information sessions.	Jan 2018	Jan 2019	Ongoing	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw as the member did not personally benefit financially.
Angie Pullen	Committee Member, Lay member	Direct - Financial	Epilepsy Action sells advertising in its magazines Epilepsy Professional and Epilepsy Today, through its trading company, BEA Trading Ltd, to a number of pharmaceutical and device manufacturers.	Jan 2018	Jan 2019	Ongoing	
Angie Pullen	Committee Member, Lay member	Direct – Non-financial	The National Institute for Health Research-Health Technology Assessment programme funded Antiepileptic drug management in	June 2011	July 2019	May 2018	Declare and participate

			<p>pregnancy: A double blind randomised trial on effectiveness and acceptability of monitoring strategies (EMPIRE study)</p> <p>Trial registration: 01253916 The trial was conducted across fifty obstetric and/or epilepsy clinics in secondary and tertiary care units in the UK from June 2011 to May 2015.</p> <p>The health technology assessment was published by NHIR in May 2018 VOLUME 22 ISSUE 23 ISSN 1366-5278</p> <p>I was a member of the steering group and advised on patient information lay summary and dissemination.</p>				<p>Agreed by GL and Chair</p> <p>Rationale: Activity ended over 1 year before pharmacology was addressed by the committee and the member did not personally benefit financially.</p>
Angie Pullen	Committee Member, Lay member	Direct – Financial professional/personal interest	<p>Arvelle therapeutics have asked Epilepsy Action my employer to attend a patient advisory board on 16th December and to find 2 people who have lived experience of focal seizures to contribute. They are paying a fee to Epilepsy Action. The Arvelle drug Cenobamate is currently going through NICE HTA as add on treatment for focal seizures</p>	December 2020	December 2020	December 2020	<p>Declare and participate</p> <p>Agreed by GL</p> <p>Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw</p>

Angie Pullen	Committee Member, Lay member	Direct – Financial professional/personal interest	<p>Presented at a webinar (Making Waves in Epilepsy- Optimising the Management of Epilepsy in Patients with Intellectual Disability) on experience of people with epilepsy and learning disabilities and epilepsy and their families. Contributed to a panel for a question and answer session for health professionals from NHS services at the end of the webinar.</p> <p>The webinar was sponsored by Eisai</p> <p>A fee was paid to Epilepsy Action my employer not to me personally.</p>	April 2021	May 2021	April 2021	<p>Declare and participate</p> <p>Agreed by GL</p> <p>Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw</p>
Ben Dorward	Committee Member, Pharmacist (adult)	Indirect – Non-financial	Committee member for the neurosciences subgroup of the UK Clinical Pharmacy Association. The UKCPA is a voluntarily subscribed not-for-profit organization to support pharmacy practice	2014	March 2021	October 2019	<p>Declare and participate</p> <p>Agreed by GL</p> <p>Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw</p>

Ben Dorward	Committee Member, Pharmacist (adult)	Direct - Financial	Paid advisory board honorarium from UCB Pharma - A single-day round table discussion about epilepsy treatment pathways; not focused on drug specific treatments.	November 2019	June 2019	November 2019	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Ben Dorward	Committee Member, Pharmacist (adult)	Direct – Non-financial professional interest	Centre for Postgraduate Pharmacy Education (CPPE). Programme guardian for a teaching programme (Focal Point) on epilepsy.	November 2016	June 2019	24 October 2019	Declare and participate Agreed by GL and NICE CA at recruitment Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Ben Dorward	Committee Member, Pharmacist (adult)	Direct – Non-financial	Providing and facilitating teaching sessions about epilepsy at a pharmacist master class.	October 2019	July 2019	4 October 2019	Declare and participate Agreed by GL.

		professional interest					Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Ben Dorward	Committee Member, Pharmacist (adult)	Direct – Financial professional interest	Was part of an advisory board for Novartis on a multiple sclerosis therapy. This was not related to epilepsy.	October 2018	October 2019	October 2018	Declare and participate Agreed by GL. Rationale: not related to the topic at hand
Ben Dorward	Committee Member, Pharmacist (adult)	Direct – Financial professional interest	Request from University of Central Lancashire to provide 5 hours of teaching on neurological conditions for a post-graduate pharmacy course. The teaching material will cover epilepsy	May 2019	May 2019	October 2019	Declare and participate Agreed by GL. Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Ben Dorward	Committee Member, Pharmacist (adult)	Direct – Financial professional interest	2 paid lectures for the Centre for Postgraduate Pharmacy Education to provide an overview of neurological conditions and pathways for treatment. Lectures	October 2019	December 2019	December 2019	Declare and participate Agreed by GL.

			provided to Pharmacists working in Care Homes as part of a national teaching program for this professional group with Health Education England. Lecture included some slides on epilepsy and the principles of drug treatment. No involvement with Pharmaceutical Companies				Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Ben Dorward	Committee Member, Pharmacist (adult)	Direct – Financial professional interest	Review the epilepsy package for the SCRIPT webpage: https://www.safeprescriber.org/	February 2020	February 2020		Declare and participate Agreed by GL. Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Ben Dorward	Committee Member, Pharmacist (adult)	Direct – Financial professional interest	Request to accuracy review update of SCRIPT e-learning module on epilepsy as part of Health Education England programme	February 2020	July 2020	July 2020	Declare and participate Agreed by GL. Rationale: despite this being a specific interest, the balance of risks is such that

							there is no need to withdraw
Ben Dorward	Committee Member, Pharmacist (adult)	Direct – Non-financial professional interest	Request from the Pharmaceutical Press to peer review an article of the management of sodium valproate and pregnancy	June 2020	July 2020	July 2020	Declare and participate Agreed by GL. Rationale: despite this being a specific interest, the balance of risks is such that there is no need to withdraw
Mo Eyeoyibo	Committee Member, Learning Disabilities Psychiatrist (adult)		No interests to declare.				

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.